Saturday, December 3, 2022

561.316.3330

Biotechnology News Magazine

Darrin Paschal Appointed New CCO of Growcentia – 25 Year Industry Veteran

Latest Posts

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hematologic cancers, including in combination with azacytidine for elderly patients with AML unable to tolerate the standard of care.

Acer Therapeutics Announces $1.5M Private Placement

The proceeds from the private placement will be used by Acer Therapeutics for working capital and general corporate purposes and, together with Acer’s existing cash and cash equivalents, are expected to be sufficient to fund the Company’s anticipated operating and capital requirements through the fourth quarter of 2022.

AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “The selection of ACI-35.030 for further development is a significant step for this collaboration. Early clinical testing showed that ACI-35.030 was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and enriched paired helical filaments (ePHF) species, both of which are closely implicated in Alzheimer’s disease (AD).

TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors

The planned clinical trial is to evaluate TransCode’s lead therapeutic candidate, TTX-MC138, in cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode Therapeutics believes that TTX-MC138 could be used as a treatment for many of these cancers.

Growcentia®, a Colorado-based biological agtech company producing microbial and natural soil and plant health solutions, today announced Darrin Paschal, a 25-year industry veteran in indoor growing, home gardening, horticulture and agriculture, as the company’s new chief commercial officer, effective Oct. 10.

“With great pleasure and excitement, we are honored to officially welcome Darrin to our team, and we have already experienced the value and leadership he provides to our staff, customers and partners,” said Scott Wiley, chief executive officer of Growcentia. “Darrin’s extensive network and his proven knowledge in arenas so integral to our success make him an ideal addition to our growing company.”

As chief commercial officer, Darrin Paschal will contribute his decades of experience in commercial horticulture, specialty agriculture and controlled environment agriculture to facilitate strategic growth and day-to-day operations of the company’s comprehensive product strategy, research and development and product development initiatives.

“Growing up in a rural farming community inspired my passion for soil health and instilled regenerative farming practices that I employ on my own farm to this day,” said Paschal. “My goal is to help companies and growers benefit from leading-edge sustainable and environmentally responsible technologies, and I’m grateful to join a like-minded organization that provides those advanced solutions.”

For most of the last decade, Growcentia has applied cutting-edge science to deliver biological and nature-based growing solutions for growers of all types of crops. Founded by three Ph.D. soil microbiologists from Colorado State University, the company’s MammothⓇ and Mammoth GardenⓇ product lines harness the power of nature to increase yields and improve plant health while reducing the impact on the environment.

To help support Growcentia’s continued expansion, the company recently opened a new headquarters in Loveland. The 30,000-square-foot facility allows the company to expand its research and development efforts and grow its national and international customer base. It features two microbiological fermentation manufacturing bays, an indoor plant trial with experimentation space and a laboratory for R&D.

“Growing up in a rural farming community inspired my passion for soil health and instilled regenerative farming practices that I employ on my own farm to this day,” said Darrin Paschal. “My goal is to help companies and growers benefit from leading-edge sustainable and environmentally responsible technologies, and I’m grateful to join a like-minded organization that provides those advanced solutions.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine